EyePoint Pharmaceuticals (EYPT) Tops Q3 EPS by 2c

EyePoint Pharmaceuticals (NASDAQ: EYPT) reported Q3 EPS of ($0.54), $0.02 better than the analyst estimate of ($0.56). Revenue for the quarter came in at $10.5 million versus the consensus estimate of $10.06 million.

For earnings history and earnings-related data on EyePoint Pharmaceuticals (EYPT) click here.

You May Also Be Interested In

• Macy's (M) Tops Q2 EPS by 28c, Beats on Revenue; Offers FY Guidance
• Pyxis Oncology Inc. (PYXS) PT Raised to $8 at H.C. Wainwright
• DuPont, Chemours and Corteva settle North Carolina PFAS claims for $455M